MMSI

MMSI

USD

Merit Medical Systems Inc. Common Stock

$92.800-1.140 (-1.214%)

リアルタイム価格

Healthcare
Medical Instruments & Supplies
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$93.940

高値

$94.230

安値

$92.640

出来高

0.62M

企業ファンダメンタルズ

時価総額

5.5B

業種

Medical Instruments & Supplies

United States

取引統計

平均出来高

0.71M

取引所

NMS

通貨

USD

52週レンジ

安値 $80.02現在値 $92.800高値 $111.45

AI分析レポート

最終更新: 2025年5月20日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

MMSI: Merit Medical Systems Inc. Common Stock - What's the Latest and What to Watch For

Stock Symbol: MMSI Generate Date: 2025-05-20 17:00:12

Alright, let's break down what's been going on with Merit Medical Systems (MMSI) based on the recent news and how the stock price has been acting.

Recent News Buzz: Feeling Pretty Good

The news flow around MMSI lately has been quite positive, no two ways about it.

First off, you've got analysts over at Needham sounding pretty confident. They've not only stuck with a "Buy" rating on the stock but also bumped up their price target, first to $108 back on May 15th, and then reiterated that $108 target just today (May 20th). When analysts raise their targets and keep a positive rating, it usually signals they see good things ahead for the company's business and, hopefully, the stock price.

Beyond the analyst chatter, the company itself has been busy. They just announced acquiring a business called Biolife Delaware. This brings in products like StatSeal® and WoundSeal®, which are basically solutions to help stop bleeding. Merit Medical is all about medical devices for procedures, so adding these hemostasis products seems like a smart move that fits right into what they already do. It could help them offer a more complete package to doctors and hospitals.

Plus, there's been good news on the product development front. They got approval in Canada for their WRAPSODY® device, which helps patients on hemodialysis. And earlier in May, they released positive 12-month results from a trial for that same WRAPSODY® product. Getting regulatory approvals and showing good trial results are big wins for a medical device company; it means they can sell more products and doctors are seeing good outcomes.

So, summing up the news: Analysts like the stock and see it going higher, the company is expanding its product line through acquisition, and key products are getting approved and showing good results. That's a solid string of positive updates.

Price Check: Bouncing Back?

Now, let's look at what the stock price has actually been doing. If you glance at the last 30 days of data, it's been a bit of a rollercoaster.

Back in late March and early April, the stock was hanging out comfortably above $100, even touching $107 briefly. But then, around April 4th, there was a pretty sharp drop, sending the price down into the low $90s and even dipping below $90 for a bit. That looked like a tough patch.

Since that April dip, the price has been bouncing around in the $90s. However, looking at the last week or so, there's been a noticeable upward trend. The price has climbed from the mid-$90s towards the high $90s, closing today (May 20th) around $98.69. It seems to be trying to recover some of that ground lost in April.

Comparing this to the AI's prediction: The AI model thinks today's price change will be minimal (0.00%), which aligns pretty well with the current price being right where it closed. But interestingly, the AI predicts slight dips over the next two days (-1.87% and -2.88%). So, while the recent trend has been up, the AI is suggesting a potential short-term pullback right after today.

Outlook & Ideas: What Now?

Putting the news and price action together, you get an interesting picture.

The news is overwhelmingly positive – analysts are bullish, the company is growing its business and getting products approved. This kind of fundamental and sentiment strength usually points towards potential upside for the stock over time. The analyst target of $108 is well above the current price, suggesting they see significant room to grow.

The price chart shows the stock has been recovering from a recent slump and is currently trending upwards, trying to get back towards those earlier $100+ levels.

However, the AI prediction throws a little caution into the very near-term mix, suggesting a possible dip in the next couple of days.

So, what does this all suggest?

Given the strong positive news and analyst backing, the overall leaning seems to be bullish for MMSI, especially when looking beyond just the next day or two. The recent price recovery supports this.

  • Potential Entry Consideration: If you're thinking about this stock, the current price area, around $98-$99, looks interesting because it's well below the analyst's target and the news is good. The AI's prediction of a slight dip could mean a chance to potentially pick up shares at a slightly lower price in the next day or two, maybe closer to the $97-$98 range mentioned in some technical indicators. But even the current level is significantly below the $108 target.
  • Potential Exit/Stop-Loss Consideration: If the stock continues its recent upward trend, a potential level to watch for taking some profits in the short term might be around the $100 mark, as suggested by some technical analysis. The analyst target is $108, which could be a longer-term goal if the positive momentum continues. On the flip side, to manage risk, setting a stop-loss order below a recent support level, perhaps around $94, could be a way to limit potential losses if the stock turns south unexpectedly, maybe following the AI's short-term prediction or if the broader market gets shaky.

Company Context

Just remember, Merit Medical is a healthcare company focused on medical instruments and supplies. Their business relies heavily on developing and selling products used in medical procedures. That's why news about product approvals (like WRAPSODY®) and acquiring companies with complementary products (like Biolife Delaware) are really important – they directly impact the company's ability to grow sales and profits. The positive analyst view likely reflects confidence in these kinds of strategic moves and product pipeline successes.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

関連ニュース

Analyst Upgrades

Piper Sandler Maintains Overweight on Merit Medical Systems, Raises Price Target to $110

Piper Sandler analyst Jason Bednar maintains Merit Medical Systems with a Overweight and raises the price target from $106 to $110.

もっと見る
Piper Sandler Maintains Overweight on Merit Medical Systems, Raises Price Target to $110
Analyst Upgrades

Needham Reiterates Buy on Merit Medical Systems, Maintains $108 Price Target

Needham analyst Mike Matson reiterates Merit Medical Systems with a Buy and maintains $108 price target.

もっと見る
Needham Reiterates Buy on Merit Medical Systems, Maintains $108 Price Target
GlobeNewswire

Merit Medical Acquires Biolife Delaware, L.L.C.

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.Acquisition projected to add

もっと見る
Merit Medical Acquires Biolife Delaware, L.L.C.
Analyst Upgrades

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108

Needham analyst Mike Matson maintains Merit Medical Systems with a Buy and raises the price target from $100 to $108.

もっと見る
Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108
GlobeNewswire

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary

もっと見る
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
GlobeNewswire

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial

AI予測Beta

AI推奨

弱気

更新日時: 2025年6月12日 18:18

弱気中立強気

60.4% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
中程度
取引ガイド

エントリーポイント

$94.11

利確

$96.34

損切り

$91.28

主要因子

DMIは弱気トレンドを示しており (ADX:17.9、+DI:4.8、-DI:5.0)、注意が必要です
現在の価格はサポートレベル(94.28ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(6,740)の7.9倍で、極めて強い買い圧力を示しています
MACD -0.1194はシグナルライン-0.1633の上にあり、強気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。